Research Paper Volume 15, Issue 24 pp 15134—15160
Experimental validation and pan-cancer analysis identified COL10A1 as a novel oncogene and potential therapeutic target in prostate cancer
Figure 5. Kaplan–Meier survival analyses of the prognostic value of COL10A1 expression level for PFS in different cancer types. PFS according to high and low expression of COL10A1 in GBM, KIRC, MESO, PRAD, SARC and UCEC from the TCGA database (A–F).